Law firm WilmerHale provides counsel to RA Capital as main financier in SAB BIO's $175 million private financing round.
SAB BIO, a clinical-stage biopharmaceutical company focused on therapies for delaying Type 1 diabetes progression in newly diagnosed patients, has announced a successful $175 million private placement financing. The funding round, announced on July 21, 2025, saw participation from a diverse group of investors.
The lead investor in the financing was RA Capital Management, with strategic investor Sanofi also participating. New investors included Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners, and Woodline Partners LP. Existing investors Sessa Capital, the T1D Fund, and ATW Partners also joined the round.
The financing involved the issuance of 1,000,000 shares of Series B nonvoting convertible preferred stock. Additionally, the Company agreed to issue warrants for additional shares of Series B nonvoting convertible preferred stock, up to an additional $284 million if exercised in full.
WilmerHale, a renowned law firm, provided representation for the financing. Chris Barnstable-Brown led the team from WilmerHale, with Scott Lunin, Frank Wang, and other members of the firm participating. WilmerHale also represented RA Capital Management in the financing.
The funds raised are intended to support the pivotal Phase 2b SAFEGUARD study of SAB-142 for delaying progression of autoimmune Type 1 Diabetes. The financing is expected to extend SAB BIO’s cash runway into mid-2028.
SAB BIO's shares are traded on the Nasdaq under the ticker symbol SABS. This private placement financing marks a significant milestone for the company as it continues its mission to develop therapies for Type 1 diabetes.
SAB BIO secured $175 million through a private placement financing, which will be utilized to support the pivotal Phase 2b SAFEGUARD study of SAB-142 for delaying progression of autoimmune Type 1 Diabetes. The financing was facilitated by the issuance of Series B nonvoting convertible preferred stock, and may be further extended through the issuance of warrants, potentially up to an additional $284 million.
